Introduction
Disease primarily inflicting prostate gland are inflammation, benign nodular enlargement, and tumors. Worldwide benign prostatic hyperplasia (BPH) affects 210 million males and is common over the age of 50 years. Carcinoma of the prostate is the most common non skin cancer in the west and the second leading cause of cancer death among men. Prostate-specific antigen is a protein produced by cells of the prostate gland. It is generally increased in diseases such as prostatitis, hyperplasia and malignancy, but the correlation between various lesion affecting the prostate gland and their corresponding rise in PSA values is not constant, and exception may occur. 

Abstract

Background: Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. It is generally increased in diseases such as prostatitis, hyperplasia and malignancy, but the correlation between various pathology affecting the prostate gland and their corresponding rise in PSA values is not constant, and exception may occur. Objectives: The aim of this study was to find out the spectrum and distribution of various prostatic lesions affecting men, with respect to their age and to find out the correlation between serum total PSA and histological findings. Materials and Method: From January 2016 to March 2019, a total of 166 patients in the age group of 39-95 years who underwent histopathology. The reports were studied retrospective and prospectively. Of these patients, 63 were being nodular hyperplasia of prostate. 70 were with existing prostatitis and 33 were adenocarcinoma. The PSA levels were estimated in our Biochemistry Department. Results: The cases were distributed in the age group 39 to 95 years. The patient of adenocarcinoma was 33 and its mean value of PSA was 1164.19 ng/ml, in case of prostatitis number of patient was 70 and its mean value was 12.74ng/ml, prostatic hyperplasia patient was 63 and mean value was 5.2ng/ml. Conclusion: The result indicate that the chances of malignancy with increasing value of PSA are more but not a rule. It can only give a clue to the histopathologist to examine the sections more thoroughly.

Keywords: Prostate Specific Antigen, Adenocarcinoma, Prostatitis.

Date of received: 27.11.2019.
Date of acceptance: 05.01.2020.
DOI: https://doi.org/10.3329/kyamcj.v11i1.47150

Examination and finally histopathological checkup are the common modalities to come into reasonable conclusion about the prostatic lesion. However, there are chances that a final diagnosis may not be achieved due to initial stage of the disease or due to concealment of malignancy by superadded inflammation. PSA has achieved a wide spread clinical use as a tumor marker in the field of prostatic pathology. It is an organ specific marker and is being used as a serological and immune-histochemical marker. Most of the studies on assaying of PSA have been conducted abroad where the immunological state of the patient, his genetic character, dietary and exercise habits are different. Very little data regarding genetic and socioeconomic status is available in Bangladesh. Keeping these points in mind a retrospective study was carried out in 2016-2019 at Khawja Yunus Ali Medical College Hospital Laboratory, Enayetpur, Sirajganj to evaluate the relationship of PSA in different prostatic pathological situation

1. Associate Professor (C,C), Department of Pathology, Khawja Yunus Ali Medical College & Hospital, Sirajganj, Bangladesh.
2. Professor & Head, Department of Pathology, Khawja Yunus Ali Medical College & Hospital, Sirajganj, Bangladesh.
3. Professor (C,C) & Head, Department of Community Medicine, Khawja Yunus Ali Medical College & Hospital, Sirajganj, Bangladesh.
4. Chief Biochemist, Department of Laboratory Service, Khawja Yunus Ali Medical College & Hospital, Sirajganj, Bangladesh.

Correspondent: Dr. Abu Sazzad Muhammad Fazlul Haque, Associate Professor (C,C), Department of pathology, Khawja Yunus Ali Medical College & Hospital, Sirajganj, Bangladesh. Mobile: 01716345591, e-mail: drfazlu08@gmail.com
Materials and Methods
From January 2016 to March 2019, a total of 166 patients in the age group of 39-95 yrs who underwent histopathological report were studied retrospective and prospectively. Of these patients, 63 were being nodular hyperplasia of prostate, 70 were with existing prostatitis and 33 were adenocarcinoma. This data was collected from the histopathology register book. All the patients underwent digital rectal examination and serum PSA measurement.

For PSA estimation five ml of blood was collected aseptically and serum was separated, liquated and frozen at -20°C for further PSA estimation. A sample is added to a reaction vessel with mouse monoclonal anti-PSA alkaline phosphatase conjugate, and paramagnetic particles coated with a second mouse monoclonal anti-PSA antibody. The PSA in the sample binds to the immobilized monoclonal anti-PSA on the solid phase while at the same time, the monoclonal anti-PSA alkaline phosphatase conjugate reacts with a different antigenic site on the sample PSA. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while un bound materials are washed away. Then the chemiluminescent substrate Lumi-Phase*530 is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of PSA in the sample. The amount of analytic in the sample is determined from a stored, multi-point calibration curve.

Results
A total number of 166 cases were studied. The cases were distributed in the age group of 39 to 95 years. In case of carcinoma prostate 33 cases (Table I) were found with PSA range from 13.9 to 8523 ng/ml (Table II) and age limitation was 39 to 90 years. In case of nodular hyperplasia of prostate 63 cases (Table I) were found with PSA range (0.55 to 99.90 ng/ml) and age limitation 50 to 85 years. In case of prostatitis cases distributed in the age group 39 to 95 years. In case of carcinoma prostate, prostatitis and hyperplasia total number of patients was 166.

Table I: Serum PSA levels in carcinoma prostate, BPH and prostatitis cases

| Serum PSA level (ng/ml) | Carcinoma (No. of pts) | BPH (No. of pts) | Prostatitis (No. of pts) |
|-------------------------|------------------------|-----------------|-------------------------|
| <4                     | Nil                    | 31              | 17                      |
| 4.1-10                 | Nil                    | 25              | 32                      |
| 10.1-20                | 4                      | 5               | 8                       |
| 20.1-50                | 3                      | 2               | 10                      |
| >50                    | 26                     | —               | 3                       |
| Total                  | 33                     | 63              | 70                      |

Table II: Serum PSA level maximum, minimum, mean and SD for Adenocarcinoma, Prostatitis and Hyperplasia

| Disease                  | Maximum | Minimum | Mean | SD   |
|--------------------------|---------|---------|------|------|
| Adenocarcinoma           | 8523.00 | 13.90   | 1165.71 | 2003.89 |
| Prostatitis              | 99.90   | 0.55    | 12.75 | 16.34 |
| Hyperplasia              | 24.50   | 0.15    | 5.20  | 4.57  |

Table II Serum PSA level in Adenocarcinoma maximum value 8523.00 ng/ml, minimum value 13.90 ng/ml, mean value 1165.71 and SD 2003.89, In Prostatitis maximum value 99.90 ng/ml, minimum value 0.55 ng/ml, mean value 12.75 and SD 16.34. In Nodular Hyperplasia maximum value 24.50 ng/ml, minimum value 0.15, mean value 5.20 and SD 4.57.

Discussion
PSA was first identified in seminal plasma by Hara et al in Japan in 1971 and was termed as gamma seminoprotein and in 1973, the protein was isolated and purified. In 1979 Wang et al isolated a tissue specific antigen from prostate and termed it as PSA, which was later found to be immunologically identical to that originally found in seminal plasma. In 1980, a serological test to measure PSA in human serum was developed.

It is a single chain glycoprotein of 240 aminoacid residue and a 4 carbohydrate side chain. It is homologous with protease of the kallikrein family, and has 34 KD molecular wt. It is organ specific produced only by prostate epithelial cells and results in liquification of the seminal coagulum. Half life of PSA is found to be 2.2 ± 0.8 days and because of this long half life, a minimum of 3-4 weeks is required for the serum PSA concentration to reach its nadir after prostate biopsy or surgery on prostate. There is no diurnal variation of serum PSA and this marker remains stable in frozen serum for a long period.

PSA concentration can be affected by any type of prostatic manipulation which includes per rectal examination, prostate biopsy, prostatectomy and prostatitis. Prostate biopsy results in significant elevation of PSA and levels do not reach a base line till the end of 4 weeks. So PSA estimation should not be done within one month of prostate biopsy. Other factors which may increase serum PSA level includes strenuous exercise, acute retention of urine and prostatic ischemia.
In our preliminary study, serum PSA levels in 33 cases of carcinoma prostate ranged from 13.9 to 8523 ng/ml with mean 1165.71 ng/ml. (Table II) In case of BPH PSA level ranged from 15 to 24.50 ng/ml (Table II) mean 5.2 ng/ml while in case of prostatitis, PSA ranged from 1.56 to 99.90 ng/ml (Table II) mean 12.74 ng/ml.

Sensitivity of PSA estimation is 100%, specify 63.9%, positive predictive value 27.96% and negative predictive value 100% where cut of value was 4ng/ml.

In the conducted by Stamey et al.1987, the mean PSA levels in case of carcinoma patients has been detected to be 5-16 times higher than the normal BPH level. In our study, the mean PSA of carcinoma is 223 times higher than the normal BPH which is far difference.

The mean age of diagnosis of prostatic carcinoma in the present study was 64.78 years. The largest percentage of cancer patients were found to be clustered in the age group of 60 to 75 years. This correlated with the study conducted by Ghafoori M et al13 and Catalona WJ et al.14 In the study done by Qulan et al, mean age for carcinoma was 64.4 years (44 to 77 years).15 According to study done by Di Silverio F et al, mean age for prostatic carcinoma was 68.9 years.16 In a study done by Kyungeun et al, mean age was 64.4 years (42 to 78 years) in 148 cases.17 Our finding was similar to the above studies.

**Conclusion**

Serum PSA is elevated marginally in patient with NPH without inflammation and patient with chronic inflammation. The cut-off value is 4ng/ml. Screening of prostatic lesions with serum PSA level is sensitive but not specific. The present study concluded that among NPH, carcinoma prostate and prostatitis, the prostatitis was the commonest lesion of prostate.

**Acknowledgement**

It is our great pleasure to express our regards to all the technologist of histopathology department, Khawja Yunus Ali Medical College and hospital for their help to supply the necessary data for the study.

**References**

1. Epstein JI. The lower urinary tract and male genital system. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Abbas, Robbins and Cotran Pathologic Basis of disease 8th ed. Philadelphia, Pennsylvania Saunders. 2010

2. Albasri A, El-Siddig A, Hussiny A, Mahrous M, Alhosaini AA, Alhujaily A. Histopathological characterization of prostate disease in madinah, Saudi Arabia. Asian Pac J Cancer Prev 2014;15:4175-4179.

3. Anderson-jackson L, McGrowder DA, Alexander-Lindo R. Prostatic specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamica. Asian Pac J Cancer Prev 2012;13:1453-1456.

4. Gittes RS. Carcinoma of prostates. N Eng J Med. 1994; 324: 236 - 245.

5. Rojer Paul, Bruel J, Hertung Rudlof, Prostate specific antigen density and age specific prostate specific values: The solution of prostates cancer screening? Eur Urol.1995;27:286-291.

6. Hara M, Inorre T, Fukuyama T. Some physio-chemical characteristics of Gamma seminoprotein, antigenic component specific for human seminal plasma. Jap J legal Med. 1971;25;25:322-325.

7. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil steril. 1973;24:134-135.

8. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol.1979:159.

9. Papsidero LD, Wang MC, Valenzuela LA. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980:40-2428.

10. Joseph E. Oesterling. Prostate specific antigen. Aestical assessment of the most useful tumor marker for adenocarcinoma prostate. J Urol.1991;145:907-923.

11. Stamey TA. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Monoger Urol. 1989;10:49.

12. Stamey TA, Yand N, Hay AR. Prostat specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
13. Ghafoori M, Vareni P, Hosseinl SJ, Asgari M, Shakiba M. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Urol J. 2009; 6(3): 182-188.

14. Catlona WJ, Smith DA, Ratliff TL, Dodda KM, Coplon DE, Yuan JJ. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324: 1156-1161.

15. Qulan J, Wollan P. The extent and multicentricity of high grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol. 1997; 28(2): 143-148.

16. Di Silverio F, Gentile V, Matteis DA, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003; 43(2): 164-175.

17. Kyungeun K, Pil JP, Jao YR, Shin D, Huh SJ, Yong MC, Limited sampling of radical prostatectomy specimen with excellent preservation of prognostic parameters of prostate cancer. Archives of Pathology and Laboratory Medicine. 2009; 133(8): 1278-1284.